Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus

Table 2 Outcomes with and without bacterial co-infection in SARS-CoV-2, influenza and RSV

Outcome	SARS-CoV-2			Influenza			RSV
Outcome	No co-infection (n = 1197)	Co-infection (n = 46)	Adjusted ratio (95% CI)^a	No co-infection (n = 566)	Co-infection (n = 209)	Adjusted ratio (95% CI)^a	No co-infection (n = 173)	Co-infection (n = 69)	Adjusted ratio (95% CI)^a
Length of stay, median (IQR), days^b	8 (5–15)	7 (4–18)	0.82 (0.54–1.23)	4 (3–7)	5 (3–10)	0.76 (0.64–0.90)	5 (3–9)	5 (3–7)	1.16 (0.86–1.56)
ICU-admission, n (%)^c	300 (25)	13 (28)	1.53 (0.87–2.69)	79 (14)	52 (25)	1.05 (0.73–1.50)	30 (17)	8 (12)	1.41 (0.58–3.47)
30-day mortality^c	132 (11)	10 (22)	1.28 (0.66–2.46)	45 (8)	10 (5)	0.72 (0.36–1.44)	15 (9)	1 (1)	0.21 (0.03–1.57)

CI, Confidence interval; ICU, Intensive care unit; IQR, Interquartile range; LRT, Lower respiratory tract; NPH, Nasoparyngeal; RSV, Respiratory syncytial virus; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
^aAdjusted for age-category, sex and Charlson comorbidity index category
^bAnalyzed by a Fine and Gray model, with presented adjusted subdistribution hazard ratios
^cAnalyzed by a Cox proportional hazards model, with presented adjusted hazard ratios

ISSN: 1471-2334